Acción VTI VISIONEERING TECHNOLOGIES, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Visioneering Technologies, Inc.

Acciones

VTI

AU000000VTI2

Mercado cerrado - Australian S.E.
Otros sitios de cotización
 05:19:06 25/06/2024 		Varia. Cinco días. Varia. 1 de enero.
0,135 AUD -3,57 % Gráfico intradía de Visioneering Technologies, Inc. -6,90 % -46,00 %
23/05 Transcript : Visioneering Technologies, Inc. - Shareholder/Analyst Call
24/04 Transcript : Visioneering Technologies, Inc., Q1 2024 Earnings Call, Apr 23, 2024

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Visioneering Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Visioneering Technologies Releases One-Year Data from Myopia Progression Control Study
Visioneering Technologies Issues Part of Shortfall from Rights Offering
VTI gibt positive vorläufige 1-Jahres-Daten aus der klinischen PROTECT-Studie auf der Jahrestagung der American Academy of Optometry bekannt
VTI Announces Positive Interim 1-Year Data from the PROTECT Clinical Trial at American Academy of Optometry Annual Meeting
Visioneering Technologies Raising Funds for Clinical Trial, Business Expansion
VTI Appoints Dr. Juan Carlos Aragón as CEO and Executive Director
Visioneering Technologies Appoints CEO
Visioneering Technologies, Inc. Announces the Appointment of Juan Carlos Aragón as Chief Executive Officer, Effective 1 October 2023
Visioneering Technologies, Inc. Announces the Appointment of Juan Carlos Aragón as Executive Director, Effective 1 October 2023
Visioneering Technologies, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
Visioneering Technologies Says Exposure to Collapsed Silicon Valley Bank is Minimal
Visioneering Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Visioneering Technologies, Inc. Announces Board Changes
Visioneering Technologies Hits 100% Enrollment Milestone for NaturalVue Multifocal Contact Lens Trial
Visioneering Technologies, Inc. Enrolls 100% of Subjects in its International Randomized Controlled Clinical Trial Known as PROTECT
Visioneering Technologies, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022
Visioneering Technologies : Appendix 4C and Business Activity Report - Jun-22 Qtr
Visioneering Technologies Reaches 50% Enrolment Milestone in Nearsightedness Clinical Trial
Visioneering Technologies, Inc. Achieves 50% Enrollment Milestone in its PROTECT International Clinical Study for Myopia Progression Control
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción VTI
  4. Noticias Visioneering Technologies, Inc.
  5. Otros idiomas